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Abstract
High dietary intake of calcium has been classified as a probable cause of prostate cancer although
the mechanism underlying the association between dietary calcium and prostate cancer risk is
unclear. The vitamin D receptor (VDR) is a key regulator of calcium absorption. In the small
intestine, VDR expression is regulated by the CDX-2 transcription factor, which binds a
polymorphic site in the VDR gene promoter. We examined VDR Cdx2 genotype and calcium
intake, assessed by a food frequency questionnaire, in 533 African American prostate cancer cases
(256 with advanced stage at diagnosis, 277 with localized stage) and 250 African American
controls who participated in the California Collaborative Prostate Cancer Study. We examined the
effects of genotype, calcium intake, and diet-gene interactions by conditional logistic regression.
Compared to men in the lowest quartile of calcium intake, men in the highest quartile had an
approximately two-fold increased risk of localized and advanced prostate cancer (odds ratio
[OR]= 2.20, 95% confidence interval [CI]= 1.40, 3.46), with a significant dose-response. Poor
absorbers of calcium (VDR Cdx2 GG genotype) had a significantly lower risk of advanced
prostate cancer (OR= 0.41, 95% CI = 0.19, 0.90). The gene-calcium interaction was statistically
significant (p=0.03). Among men with calcium intake below the median (680 mg/day), carriers of
the G allele had an approximately 50% decreased risk compared to men with the AA genotype.
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These findings suggest a link between prostate cancer risk and high intestinal absorption of
calcium.
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Introduction
The relationship between diets high in calcium and risk of prostate cancer has been the
subject of numerous epidemiologic studies. In a recent review of this literature, the World
Cancer Research Fund (WCFR) classified calcium as a probable cause of prostate cancer1.
The Agency for Health Care Research and Quality (AHCRQ) reached a similar conclusion2.
The assessment of the WCFR was based on examination of 9 cohort and 12 case-control
studies. On meta-analysis, higher intake of calcium was associated with increased risk of
prostate cancer, consistent with a dose-response relationship in the cohort studies. The
AHCRQ report considered that of the four cohort studies with the highest methodologic
quality, three showed that diets high in calcium were associated with an increased risk of
advanced or fatal disease. Recently, two prospective studies showed that serum levels of
calcium that are high but within the normal reference range (high normocalcemia) were
associated with a 2–3 fold increase in prostate cancer mortality3–4. Because levels of ionized
calcium in serum are increased after absorption of a moderate dose of calcium, we
hypothesized that prostate cancer risk may be influenced by polymorphisms in genes that
influence the efficiency of calcium absorption.
Many of the genes affecting calcium absorption are regulated by the vitamin D receptor
(VDR)5–6. In the small intestine, VDR expression is regulated by the tissue-specific
transcription factor, CDX-27 which binds a site in the VDR upstream 1e promoter8. This
CDX-2 binding site harbors a single nucleotide A/G polymorphism (denoted Cdx2). The
CDX-2 protein binds more efficiently to the A than to the G allele, and the A allele has been
shown to more efficiently drive transcription in in vitro reporter gene assays9. The VDR
Cdx2 low activity G allele has been associated consistently with lower bone mineral density
in candidate gene studies10, and data from genome-wide association studies (GWAS)
support these findings. Although the association did not attain genome-wide significance
(p=0.0007), a SNP (rs7132324) tightly linked to the Cdx2 SNP (D'=0.967) was among the
top 0.2% of hits for bone mineral density at the hip11. Although the effect of the Cdx2 SNP
on intestinal calcium absorption remains to be experimentally verified, these data suggest
that the differences observed between alleles in vitro influence intestinal calcium absorption
in vivo.
We hypothesized that the high activity A allele, which is common in populations of African
origin, may contribute to the high prostate cancer incidence and mortality rates and younger
ages at diagnosis observed in African Americans compared to other racial/ethnic
groups12–13. We examined dietary calcium intake and VDR Cdx2 genotype among 533
African American cases (256 with advanced stage at diagnosis; 277 with localized stage)
and 250 African American controls from the California Collaborative Prostate Cancer
Study, a population-based multiethnic case-control study that had a high proportion of cases
diagnosed with aggressive prostate cancer.
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The study population from the San Francisco Bay area and Los Angeles County has been
described in detail previously14. Cases were identified by the Greater Bay Area Cancer
Registry, the Los Angeles County Cancer Surveillance Program, and the Los Angeles
County Cancer Registry. Five hundred fifty-nine African American cases (including 377
from Southern California and 182 from Northern California) completed the interview.
Twenty-six cases did not have definitive stage and were excluded, leaving 533 cases. Four
hundred fifty-four cases (246 advanced and 208 localized) provided a biospecimen.
Biospecimens were not collected from localized cases at the Northern California site.
In both studies, advanced prostate cancer was defined according to SEER (Surveillance
Epidemiology and End Results) 1995 pathologic and clinical extent of disease codes. Of the
533 participating cases, 256 (116 from Northern California and 140 from Southern
California) were diagnosed with advanced stage, 277 (66 from Northern California and 211
from Southern California) were diagnosed with localized disease.
Controls were identified through random-digit dialing and from random selections from the
rosters of beneficiaries of the Health Care Financing Administration at the Northern
California site and by a standard neighborhood walk algorithm15 at the Southern California
site. Controls were frequency matched to cases on self-reported race/ethnicity and expected
5-year age distributions. Two hundred fifty controls (including 162 from Southern
California and 88 from Northern California) completed the interview and 245 provided a
biospecimen.
The study was approved by the Institutional Review Boards of the Cancer Prevention
Institute of California (formerly the Northern California Cancer Center) and the University
of Southern California. Written informed consent was obtained for all study participants.
Data Collection
Trained interviewers conducted in-person interviews and administered a structured
questionnaire that asked about demographic background, lifestyle factors (physical activity,
alcohol consumption, smoking), body size, use of supplements containing calcium, family
history of prostate cancer in first-degree relatives, medical history and screening for prostate
cancer. A 74-item food frequency questionnaire adapted from Block’s Health History and
Habits Questionnaire16 assessed usual dietary intake during the reference year, defined as
the calendar year before diagnosis for cases and the year before selection into the study for
controls. The interviewers also took three measurements of standing height and weight
which were averaged. Calcium intake was assessed from single calcium tablets,
multivitamin pills, and calcium-based antacids, such as Tums, Rolaids, Alka-Mints or Chooz
Antacid gum. Data were collected on age at first use, frequency of use, and duration of use.
Exposure Variables
Dietary questionnaires from subjects reporting total energy intake greater than 6000 or less
than 600 kilocalories per day (33 cases and 10 controls) were considered to be unreliable
and were excluded from the analysis, leaving 500 cases and 240 controls with dietary
information.
We derived two measures of calcium exposure, including total calcium from foods,
beverages and supplements, and dietary calcium from foods and beverages only. Cut points
were selected based on the calcium intake of controls. Calcium supplementation was divided
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into dichotomous categories reflecting usual daily calcium contained in multivitamins (400
mg/day) vs. less than 400 mg/day. Body mass index (BMI) was calculated as reported
weight in the reference year (in kg) divided by measured height squared (in meters [m]) and
dichotomized as obese (BMI ≥30) and non-obese (BMI <30).
Genotyping
The CDX-2 protein binding site SNP10 (rs11568820) was genotyped on the TaqMan
7900HT Sequence Detection System using the TaqMan Core Reagent Kit (Applied
Biosystems, Foster City, CA). PCR reactions were carried out as recommended by the
manufacturer. The following primer and minor groove binder probe sequences were used:
forward primer 5’-CATTGTAGAACATCTTTTGTATCAGGAACT-3’, reverse primer 5’-
GGTCTTCCCAGGACAGTATTTTTCA-3’, G allele FAM- AGGTCACAGTAAAAAC-3’,
and A allele VIC-AGGTCACAATAAAAAC-3’. Ten percent of samples were blindly
replicated and samples with known genotype were included as controls on each run. Clusters
were manually called without knowledge of case-control status. There were no discrepancies
among replicate samples. Genotypes were called for 447 cases and 233 controls, giving a
call rate of 97%.
Statistical Analysis
Allele frequencies were estimated by gene counting. Tests for departures from Hardy-
Weinberg equilibrium among controls were conducted by comparing observed and expected
genotype frequencies using a Chi Square test.
A matching variable for conditional logistic regression was constructed by creating study
site/socio-economic status (SES) bins, as previously described14. Odds ratios (OR) and 95%
confidence intervals (CI) were estimated by fitting conditional logistic regression models,
using study site/SES as the matching variable and adjusting for age (continuous variable)
and family history of prostate cancer in first-degree relatives (yes or no). Calcium was
categorized according to quartiles among the controls. Dose-response trends were assessed
by including quartile as an ordinal variable in logistic regression models. Tests of interaction
were conducted by including cross-product terms in the conditional logistic models and
conducting a 1 degree of freedom likelihood ratio test.
Results
Characteristics of participants are shown in Table 1. The median age at diagnosis was 64
years. On average, advanced cases were three years younger at diagnosis than localized
cases. Cases and controls were similar with respect to education, socioeconomic status, and
body mass index. Cases were more likely to report a family history of prostate cancer and
consumed more calcium than did controls.
The majority of participants (82% of cases and 76% of controls) consumed less than the
recommended intake of 1200 mg of calcium per day17. The predominant sources of dietary
calcium were similar for cases and controls: dairy products (45%), followed by vegetables
(predominantly spinach, other greens, and broccoli) (25%), and grains (including corn
tortillas) (15%). Dietary calcium and total calcium showed similar patterns of increased risk
of both advanced and localized disease associated with increasing intake (Table 2). Men in
the highest quartile of total calcium intake (> 1059 mg/day) had a more than two-fold
increased risk of prostate cancer (advanced or localized) vs. men in the lowest quartile (<488
mg/day) (OR = 2.20, 95% CI= 1.40, 3.46, p for trend= 0.01). Intake of calcium from
supplements was low, with fewer than 5% of men consuming at least 400 mg/day of
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supplemental calcium. However, consumers of 400 mg/day or more had a significantly
increased risk for advanced prostate cancer (OR= 3.15, 95% CI= 1.09, 9.15) (Table 2).
The VDR Cdx2 minor (G) allele frequency was 28%. Genotype frequencies among the
controls were in Hardy-Weinberg equilibrium. TheVDR Cdx2 genotype was significantly
associated with advanced, but not localized, prostate cancer (Table 3). Risk decreased with
increasing number of G alleles (p trend = 0.02). Compared to men with genotype AA, those
with the GG genotype were 59% less likely to have been diagnosed with advanced prostate
cancer. When combining all cases (advanced plus localized), the reduction in risk for
genotype GG vs. AA was slightly attenuated (42%) and was of borderline statistical
significance (p=0.09).
The relationship between Cdx2 genotype and risk of advanced prostate cancer was modified
by calcium intake (p for interaction = 0.03) (Table 3). Among men with calcium intake
below the median, carriers of the G allele had an approximately 50% decreased risk
compared to those with genotype AA. Among men with calcium intake above the median,
Cdx2 G alleles were not associated with reduced risk of advanced prostate cancer. There
was no association between Cdx2 genotype and risk of localized prostate cancer, regardless
of the level of calcium intake. High calcium intake was a risk factor for advanced prostate
cancer among men of all genotypes (Table 4), although the association was of borderline
statistical significance among men with genotype AA (p=0.08).
The relationship between dietary calcium and prostate cancer risk was modified by obesity
(Table 5). High calcium intake was a risk factor among both obese and non-obese men,
although the association appeared to be stronger among the obese (p for interaction = 0.06).
Data were too sparse to determine whether the relationship between VDR Cdx2 genotype
and prostate cancer risk was modified by obesity, since genotype was a risk factor only for
advanced disease.
Discussion
Our finding of an association between dietary calcium and prostate cancer risk is consistent
with a sizable literature on dietary calcium and prostate cancer (see reviews18–19). However,
few studies have examined genotypes related to calcium absorption. To our knowledge, the
VDR Cdx2 polymorphism has been examined in four prostate cancer studies, with
inconsistent findings. Two studies examined the Cdx2 polymorphism with respect to sun
exposure and prostate cancer risk. A UK study in an exclusively Caucasian population found
a two-fold increased risk among carriers of the A allele, consistent with our findings, but
that finding was limited to men with high sunlight exposure20 [Bodiwala et.al, 2004].
Conversely, in a U.S. study of non-Hispanic white men, we found no significant association
between VDR Cdx2 genotype and advanced prostate cancer risk, regardless of sun
exposure21. Cdx2 genotype was examined in conjunction with serum vitamin D levels in the
Physician’s Health study22. Although there was a significant interaction between VDR Cdx2
genotype and vitamin D status, genotype was not significantly related to prostate cancer risk
within strata defined by serum 25(OH)D levels (deficient/sufficient). Finally, in a study that
did not examine vitamin D status or sunlight exposure, Torkko et al. found a borderline
significant association between the A allele and decreased prostate cancer risk, among
Hispanic but not among non-Hispanic White men23.
Our finding that the high transcription A allele is associated with increased prostate cancer
risk is not explained by the well-documented anti-proliferative, pro-differentiating effects of
the VDR and its ligands on prostate epithelial cells24. Increased expression of VDR in the
prostate should decrease, not increase, risk. Furthermore, VDR Cdx2 genotype should not
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affect prostatic VDR expression in the absence of the CDX-2 transcription factor, which is
generally believed to be restricted to the intestine. However, it is noteworthy that CDX-2
expression has been reported in some other organs, including the prostate. In 70 radical
prostatectomy specimens, Herawi et al. observed CDX-2 staining in 5.7% of the specimens.
No staining was observed in any of 185 metastatic prostate tumors25. The role of this protein
in prostate tissue is presently unclear. However, the relative rarity of its expression suggests
that it is unlikely to significantly influence the results of this study.
We believe that our findings are intelligible on the hypothesis that high calcium absorption
genotypes and/or diets high in calcium increase serum calcium levels and the increase in
serum calcium affects prostate cancer cells. Prostate cells, including prostate cancer cells,
possess both the calcium-sensing receptor26 and calcium-dependent voltage-gated
channels27 which respond to an increase in calcium with an increase in proliferation and a
decrease in apoptosis. Levels of total serum calcium are generally very stable, and are little
influenced by dietary intakes over a wide range of intake28. However, the results of carefully
conducted metabolic studies indicate that serum levels of ionized calcium, the biologically
active fraction of total serum calcium, increase significantly for several hours after calcium
intake29–30. High normal levels of serum and ionized serum calcium have been associated
with increased risk of fatal prostate cancer in two prospective epidemiologic studies3–4.
Because serum calcium is presumed to promote prevalent (existing) cancer, rather than
having an effect on the initiation of cancer, this interpretation is consistent with the
observation that VDR Cdx2 genotype was associated with advanced but not localized
disease.
For advanced disease, we observed a statistical interaction between dietary calcium intake
and genotype. The high absorption variant conferred less risk among men consuming higher
levels of calcium. Although vitamin D aids calcium absorption, on a typical diet containing
1000 mg of calcium, the majority of calcium absorption is passive (vitamin D-
independent)31. The passive absorption of calcium may explain why men who consume
greater amounts of calcium are at increased prostate cancer risk, regardless of genotype.
We also observed a borderline significant interaction between calcium intake and obesity,
with calcium being a stronger risk factor among the obese than the non-obese. This finding
contrasts with a report from the Singapore Health Study which found calcium to be a risk
factor only among thin men (BMI<22.9 kg/m2)32. However the interaction between calcium
and BMI in that study was not statistically significant.
Although numerous studies indicate that calcium is associated with an increased risk of
prostate cancer, particularly of advanced and or fatal disease, other studies have suggested
that adequate (vs. deficient) levels of 25-OHD are associated with a decreased risk of
subsequent prostate cancer. As the “classic” role of vitamin D is to increase the efficiency of
calcium uptake, the literature for serum vitamin D and for calcium appears conflicting.
However this apparent conflict can be understood by considering the “non-classical”
(autocrine/paracrine) role of vitamin D in the prostate. Prostate cells possess 1-alpha
hydroxylase and convert 25-OHD into 1,25(OH)2D, which exerts prodifferentiating and
antiproliferative effects on prostate cancer cells33. Thus the classical (calcium-mediated) and
non-classical roles of vitamin D operate “against” each other to influence prostate cancer
risk, probably through different mechanisms. Although it had been speculated that the
increased risk for prostate cancer that is associated with higher levels of dietary calcium was
due to a reduction in the hepatic conversion of 25-OHD into 1,25(OH)2D by calcium34, this
hypothesis has not been supported by subsequent investigations35.
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It is important to note that although some studies have reported an increased risk of prostate
cancer with low levels of vitamin D21,36, these have not been confirmed by some other
investigations. Many subsequent studies of serum 25-OHD and prostate cancer risk have
been null, and some have reported an increased risk of prostate cancer with both low and
high levels of 25-OHD37–38. A positive effect of serum calcium on prostate cancer risk may
confound the relationship between 25(OH)D and prostate cancer risk in some studies, which
may account for some discrepant results in the literature39.
Our study has several limitations, including its retrospective design which could have
introduced recall bias in the reporting of calcium intake. However, our findings for calcium
intake are consistent with those of several prospective studies, where recall bias obviously is
not a contributor. Similarly, although we measured calcium intake, we did not measure
serum calcium. Future studies would benefit from including measurements of serum total
and ionized calcium.
Strengths of the study include its population-based design and the oversampling of cases
with advanced-stage disease, which allowed us to distinguish stage-specific genotype-diet
interactions that would have been difficult or impossible to detect in a case series that
consisted mainly of early-stage disease. Finally, few epidemiologic studies of diet and
prostate cancer have included large numbers of African American cases.
Population stratification is a potential confounding issue in our study. The VDR Cdx2 A
allele is associated with both increased prostate cancer risk and with African ancestry. It
could be that the A allele is simply marking those men with increased African ancestry and
therefore at increased risk due to some other factor that is associated with African ancestry.
In fact, among the 518 men for whom genetic ancestry estimates were available, adjusting
for European ancestry did not alter the results. The ancestry-adjusted odds ratio comparing
genotype GG to AG/AA for advanced cases vs. controls was 0.37 after ancestry adjustment
(vs. an unadjusted OR of 0.38).
The more active A allele is most prevalent in populations of African origin (98% in
Yorubans in Ibadan, 89% in Luhya in Kenya, 71% in African Americans of the U.S.
Southwest; in contrast to 45% in Japanese in Tokyo, Japan and 20% in Utah residents with
ancestry from northern and western Europe)40. Prostate cancer incidence rates in African
Americans are 36% higher than those of non-Hispanic Whites, and African Americans are
diagnosed at younger ages and are twice as likely to die of the disease (SEER 2003–2007)13.
Therefore, by promoting efficient calcium absorption even on a relatively low calcium diet,
the ancestral African VDR Cdx2 allele may contribute to racial/ethnic disparities in prostate
cancer incidence and mortality.
In conclusion, our data support the hypothesis, substantiated in many epidemiologic studies,
that dietary calcium is causally related to prostate cancer risk18–19. Our finding that prostate
cancer risk is increased among high absorbers of calcium adds to the biological plausibility
of the calcium hypothesis, for which the underlying mechanism has been a subject of
considerable debate34–35,41–42. Because calcium is essential for bone health and appears to
protect against colorectal cancer (and possibly other diseases)1, we must be cautious about
making public health recommendations to limit calcium intake. Our data indicate that,
although calcium intake increases prostate cancer risk in African American men as a group,
it is associated with a significantly greater risk among high absorbers of calcium (men with
the AA genotype). If confirmed by other dietary-seroepidemiologic studies, African
American men with the AA genotype may be advised to restrict their calcium intake in order
to reduce their risk of developing prostate cancer.
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Table 1





N (%) N (%) N (%)
Age (years)
<=49 17 (7%) 15 (6%) 13 (5%)
50–59 63 (25%) 79 (31%) 56 (20%)
60–69 105 (42%) 106 (41%) 114 (41%)
70–79 60 (24%) 53 (21%) 78 (28%)
>=80 5 (2%) 3 (1%) 16 (6%)
mean (SD) 63.5 (9.15) 62.7 (8.46) 65.8 (8.85)
Education
High School or less 99 (40%) 120 (47%) 120 (43%)
College Degree/Some College 95 (38%) 79 (31%) 111 (40%)
Post Graduate 49 (20%) 57 (22%) 45 (16%)
Unknown 7 (2%) 0 (0%) 1 (<1%)
SES (census tract-based)
1 = Low 51 (20%) 69 (27%) 96 (35%)
2 71 (28%) 54 (21%) 70 (25%)
3 57 (23%) 63 (25%) 58 (21%)
4 48 (19%) 45 (18%) 33 (12%)
5= High 23 (9%) 25 (10%) 20 (7%)
Family History of Prostate
Cancer 217 (87%) 195 (76%) 214 (77%)
No 28 (11%) 61 (24%) 63 (23%)
Yes 5(2%) 0 (0%) 0(0%)
Unknown Mean (SD) Mean (SD) Mean (SD)
BMI (Kg/m2) 28.8 (5.5) 28.3 (5.5) 28.5 (4.8)
Calcium Intake
Total Calcium (mg/day) 818 (474) 979 (577) 945 (510)
Dietary Calcium (mg/day) 755 (444) 890 (517) 869 (497)
Supplemental Calcium (mg/day) 64 (155) 89 (217) 75 (130)
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TABLE 4
Advanced Prostate Cancer and VDR CDX-2 Polymorphism Stratified by Total Calcium Intake
Genotype Total Calcium
VDR-CDX-2 Low Calcium
< = 680 mg/day
High Calcium
> 680 mg/day
OR (95% CI) OR (95% CI) p - value
AA 1.00 (ref) 1.58 (0.95, 2.63) p= 0.08
AG /GG 0.43 (0.22, 0.82) 1.44 (0.83, 2.49) p= 0.01
p for trend p = 0.03 p = 0.70
Model adjusted for age and family history of prostate cancer
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TABLE 5
Total Calcium Intake and Prostate Cancer Risk, Stratified by Obesity
<30 BMI (Non-Obese) Controls All Cases vs. Controls
N = 161 N = 353 OR (95% CI)
Total Calcium† N (%) N (%)
< = 680 mg/day 81 (50%) 128 (36%) 1.0 (ref)
> 680 mg/day 80 (50%) 225 (64%) 1.80 (1.23, 2.65)
p for trend p=0.003
> = 30 BMI (Obese) Controls All Cases vs. Controls
N = 78 N = 152 OR (95% CI)
Total Calcium† N (%) N (%)
< = 680 mg/day 38 (49%) 29 (21%) 1.0 (ref)
> 680 mg/day 40 (56%) 116 (79%) 3.70 (1.99, 6.90)
p for trend p <0.01
p for Interaction p= 0.06
†
Total Calcium= dietary calcium and supplements
Models adjusted for age and family history of prostate cancer
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